207 related articles for article (PubMed ID: 7881474)
1. Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications.
Kuczyk MA; Serth J; Hervatin C; Arndt H; Derendorf L; Thon WF; Jonas U
World J Urol; 1994; 12(6):345-51. PubMed ID: 7881474
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
3. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
4. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
[TBL] [Abstract][Full Text] [Related]
5. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
Serth J; Kuczyk MA; Bokemeyer C; Hervatin C; Nafe R; Tan HK; Jonas U
Br J Cancer; 1995 Jan; 71(1):201-5. PubMed ID: 7819040
[TBL] [Abstract][Full Text] [Related]
6. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
7. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
[TBL] [Abstract][Full Text] [Related]
8. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.
Babjuk M; Soukup V; Mares J; Dusková J; Sedlácek Z; Trková M; Pecen L; Dvorácek J; Hanus T; Kocvara R; Novák J; Povýsil C
Int Urol Nephrol; 2002; 34(4):495-501. PubMed ID: 14577491
[TBL] [Abstract][Full Text] [Related]
9. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
12. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
14. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
17. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
[TBL] [Abstract][Full Text] [Related]
18. p53 expression predicts progression and poor survival in T1 bladder tumours.
Llopis J; Alcaraz A; Ribal MJ; Solé M; Ventura PJ; Barranco MA; Rodriguez A; Corral JM; Carretero P
Eur Urol; 2000 Jun; 37(6):644-53. PubMed ID: 10828662
[TBL] [Abstract][Full Text] [Related]
19. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis.
Inagaki T; Ebisuno S; Uekado Y; Hirano A; Hiroi A; Shinka T; Ohkawa T
Int J Urol; 1997 Mar; 4(2):172-7. PubMed ID: 9179692
[TBL] [Abstract][Full Text] [Related]
20. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
